Holen Sie sich die Stockscreener-App
2.345
2.85%
0.065
Handel nachbörslich:
2.34
-0.005
-0.21%
Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten
What's Going On With Black Diamond Therapeutics Stock Tuesday? - Benzinga
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data - The Globe and Mail
Black Diamond Therapeutics lung cancer drug shows 15.2-month PFS in phase 2 study - MSN
Black Diamond Therapeutics (BDTX) Shares Tumble Nearly 35% on Clinical SetbackExpert Trade Signals - Newser
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Stifel reiterates Black Diamond Therapeutics stock rating at Buy By Investing.com - Investing.com Canada
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - The Manila Times
BDTX Stock Price, Quote & Chart | BLACK DIAMOND THERAPEUTICS I (NASDAQ:BDTX) - ChartMill
Black Diamond Therapeutics Reports Positive Phase 2 Results for Silevertinib in Frontline NSCLC With EGFR Non-Classical Mutations, Highlighting Strong CNS Activity and mPFS of 15.2 Months 13 - Minichart
Black Diamond Highlights Positive Phase 2 Silevertinib Lung Cancer Data - TipRanks
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study - inkl
Black Diamond reports silevertinib trial results in lung cancer By Investing.com - Investing.com Australia
Black Diamond reports silevertinib trial results in lung cancer - Investing.com
Black Diamond Therapeutics Announces Encouraging Phase 2 Trial Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations - Quiver Quantitative
Positive NSCLC trial results boost Black Diamond (NASDAQ: BDTX) drug hopes - Stock Titan
Black Diamond Therapeutics Announces Positive Phase 2 - GlobeNewswire
Lung cancer trial: silevertinib shows 86% brain response, 60% tumor response - Stock Titan
BDTX shares gain 11% in a week: Here's what you should know - MSN
SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX - RTTNews
BDTX Technical Analysis | Trend, Signals & Chart Patterns | BLACK DIAMOND THERAPEUTICS I (NASDAQ:BDTX) - ChartMill
Black Diamond to present phase 2 silevertinib trial data Thursday By Investing.com - Investing.com South Africa
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results From Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - 富途牛牛
Black Diamond to present phase 2 silevertinib trial data Thursday - Investing.com
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - The Manila Times
Black Diamond Therapeutics to Host Webcast for Investors - GlobeNewswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TradingKey - TradingKey
Black Diamond Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BDTX Shares Gain 11% in a Week: Here's What You Should Know - TradingView
Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Black Diamond Therapeutics (NASDAQ:BDTX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Black Diamond Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Black Diamond Therapeutics | 8-K: Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating - Moomoo
Black Diamond: Q1 Earnings Snapshot - marketscreener.com
Black Diamond starts GBM Phase 2 dosing as ASCO lung data nears - Stock Titan
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
Black Diamond Therapeutics (NASDAQ: BDTX) swings to Q1 2026 loss as Servier upfront drops out - Stock Titan
Black Diamond Therapeutics (Nasdaq: BDTX) swings to Q1 loss as silevertinib trials advance - Stock Titan
MSN Money - MSN
Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Monday - MarketBeat
Implied volatility surging for Black Diamond Therapeutics stock options - MSN
HC Wainwright Issues Positive Forecast for BDTX Earnings - MarketBeat
BDTX - Finviz
Why is Black Diamond (BDTX) up 19.3% since last earnings report? - MSN
[ARS] Black Diamond Therapeutics, Inc. SEC Filing - Stock Titan
Black Diamond Therapeutics (BDTX) outlines 2026 virtual meeting and Say-on-Pay votes - Stock Titan
BDTX Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Given New $11.00 Price Target at BTIG Research - MarketBeat
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Implied Volatility Surging for Black Diamond Therapeutics Stock Options - Zacks Investment Research
BDTX: What silevertinib data say about EGFR NSCLC upside - MSN
Will Upcoming Catalysts Help Black Diamond Investors Breathe Easy? - RTTNews
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):